drugset
drugset / Trial / NCT04866056

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

NCT04866056 ↗

Phase 1/2 Terminated 1 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial studies how well Jaktinib and azacytidine work in treating patients with myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis. Giving Jaktinib and azacytidine may be an effective treatment for myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis.

Timeline

Start
2021-09-30
Primary completion
2022-06-10
Completion
2022-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified — Subcutaneous
Subject Jaktinib Unknown — Oral

Indications

myelodysplastic syndrome myelofibrosis